MX366296B - Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida. - Google Patents

Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.

Info

Publication number
MX366296B
MX366296B MX2015007189A MX2015007189A MX366296B MX 366296 B MX366296 B MX 366296B MX 2015007189 A MX2015007189 A MX 2015007189A MX 2015007189 A MX2015007189 A MX 2015007189A MX 366296 B MX366296 B MX 366296B
Authority
MX
Mexico
Prior art keywords
compositions
antibodies
lenalidomide
kits
disclosed
Prior art date
Application number
MX2015007189A
Other languages
English (en)
Other versions
MX2015007189A (es
Inventor
Tomkinson Blake
C Hann Byron
G Martin Thomas Iii
T Aftab Blake
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2015007189A publication Critical patent/MX2015007189A/es
Publication of MX366296B publication Critical patent/MX366296B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a las composiciones y los kits que comprenden los anticuerpos antiCD38 y los compuestos de lenalidomida. También se divulgan los métodos para tratar cánceres, como mieloma múltiple, en los pacientes con las composiciones y los kits.
MX2015007189A 2012-12-07 2013-12-06 Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida. MX366296B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (2)

Publication Number Publication Date
MX2015007189A MX2015007189A (es) 2016-03-21
MX366296B true MX366296B (es) 2019-07-04

Family

ID=50884019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007189A MX366296B (es) 2012-12-07 2013-12-06 Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX2019008065A MX2019008065A (es) 2012-12-07 2015-06-05 Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008065A MX2019008065A (es) 2012-12-07 2015-06-05 Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.

Country Status (31)

Country Link
EP (2) EP2928495B1 (es)
JP (2) JP6499971B2 (es)
KR (2) KR102193045B1 (es)
CN (1) CN105263520B (es)
AR (1) AR093844A1 (es)
AU (2) AU2013355064B2 (es)
BR (1) BR112015012987A2 (es)
CA (1) CA2893946A1 (es)
CL (2) CL2015001558A1 (es)
CY (2) CY1122478T1 (es)
DK (1) DK2928495T3 (es)
ES (1) ES2731548T3 (es)
HK (1) HK1215536A1 (es)
HR (1) HRP20191034T1 (es)
HU (3) HUE044142T2 (es)
IL (2) IL239234B (es)
LT (2) LT2928495T (es)
MX (2) MX366296B (es)
MY (1) MY191601A (es)
NL (1) NL301079I2 (es)
NZ (1) NZ709215A (es)
PH (1) PH12015501263A1 (es)
PL (1) PL2928495T3 (es)
PT (1) PT2928495T (es)
RS (1) RS58829B1 (es)
RU (1) RU2698911C2 (es)
SG (3) SG10201704536PA (es)
SI (1) SI2928495T1 (es)
TW (2) TW201919699A (es)
UA (1) UA118255C2 (es)
WO (1) WO2014089416A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EA202190808A2 (ru) 2015-11-03 2021-12-31 Янссен Байотек, Инк. Составы антител к cd38 для подкожного введения и их применение
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
WO2019199132A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286498B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드의 경구용 코팅 정제 조성물
WO2020187718A1 (en) * 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2021113739A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
CN117751144A (zh) * 2021-08-02 2024-03-22 杭州优诺健生物科技有限公司 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20080153976A1 (en) * 2004-12-21 2008-06-26 Nippon Kayaku Kabushiki Kaisha Epoxy Resin, Epoxy Resin Composition, And Cured Material Thereof
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
SI2081595T1 (sl) * 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
RU2595839C2 (ru) * 2010-09-27 2016-08-27 МорфоСис АГ Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
SG10201704536PA (en) 2017-07-28
SG11201504315WA (en) 2015-07-30
KR20150091165A (ko) 2015-08-07
EP2928495A1 (en) 2015-10-14
EP3597191A1 (en) 2020-01-22
HUE044142T2 (hu) 2019-09-30
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
CL2018003292A1 (es) 2019-02-01
MY191601A (en) 2022-07-01
PL2928495T3 (pl) 2019-09-30
JP2016506388A (ja) 2016-03-03
CN105263520A (zh) 2016-01-20
MX2015007189A (es) 2016-03-21
RS58829B1 (sr) 2019-07-31
AU2013355064B2 (en) 2018-05-24
DK2928495T3 (da) 2019-06-24
AU2013355064A1 (en) 2015-07-09
CN105263520B (zh) 2020-03-13
CY2020040I2 (el) 2021-05-05
SG10201913783PA (en) 2020-03-30
TWI670062B (zh) 2019-09-01
ES2731548T3 (es) 2019-11-15
RU2698911C2 (ru) 2019-09-02
SI2928495T1 (sl) 2019-07-31
JP6499971B2 (ja) 2019-04-10
CY1122478T1 (el) 2021-01-27
HUS2000050I1 (hu) 2020-12-28
PT2928495T (pt) 2019-07-04
LTPA2020537I1 (lt) 2020-12-28
HUS2000051I1 (hu) 2020-12-28
IL239234B (en) 2021-05-31
EP2928495A4 (en) 2016-05-11
PH12015501263A1 (en) 2015-08-17
MX2019008065A (es) 2019-09-23
EP2928495B1 (en) 2019-03-27
RU2015127089A (ru) 2017-01-13
WO2014089416A1 (en) 2014-06-12
AU2018211258A1 (en) 2018-08-16
CL2015001558A1 (es) 2015-10-02
NZ709215A (en) 2020-08-28
TW201919699A (zh) 2019-06-01
BR112015012987A2 (pt) 2017-09-12
KR102193045B1 (ko) 2020-12-18
CY2020040I1 (el) 2021-03-12
HK1215536A1 (zh) 2016-09-02
LT2928495T (lt) 2019-07-10
KR20200143503A (ko) 2020-12-23
UA118255C2 (uk) 2018-12-26
HRP20191034T1 (hr) 2019-08-23
AR093844A1 (es) 2015-06-24
IL239234A0 (en) 2015-07-30
CA2893946A1 (en) 2014-06-12
JP2019070020A (ja) 2019-05-09
IL282542A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
NZ739252A (en) Monoclonal antibodies against bcma
PH12014501108A1 (en) Anti-il-36r antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
MX2015013163A (es) Complejos multiespecificos multivalente y monovalentes y sus usos.
MX2019008212A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
MX2016012371A (es) Anticuerpos multiespecificos.
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
EP2725901A4 (en) COMPOSITIONS, METHODS AND NECESSARY FOR TREATING LEUKEMIA
EA201591709A1 (ru) 5-бром-индирубины
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
WO2013013238A3 (en) Compounds and related compositions and methods of use
TN2014000207A1 (en) Anti il-36r antibodies
WO2015024000A3 (en) Mitochondrially-targeted electrophilic compounds for cancer treatment
NZ723535A (en) Combination therapies with anti-cd38 antibodies
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
FG Grant or registration